Cargando…
Commment on the review entitled “A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer” by Chiva LM and Gonzalez-Martin A.
• We raised some methodological concerns and made some comments on the systematic review by Chiva and colleague. • To state that Cytoreduction & HIPEC is not beneficial in front line and platinum sensitive recurrence is highly disputable. • Anyway, the combined treatment should be offered in the...
Autores principales: | Deraco, Marcello, Kusamura, Shigeki, Baratti, Dario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750010/ https://www.ncbi.nlm.nih.gov/pubmed/26937478 http://dx.doi.org/10.1016/j.gore.2015.11.002 |
Ejemplares similares
-
Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites
por: Jiao, Jie, et al.
Publicado: (2020) -
Past, Present, and Future of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer
por: Mishra, Mona, et al.
Publicado: (2021) -
Prophylactic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer—A Systematic Review
por: Brenkman, H. J. F., et al.
Publicado: (2019) -
Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations
por: Pelz, Joerg OW, et al.
Publicado: (2006) -
The use of Hypotension Prediction Index in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Gangakhedkar, Gauri R., et al.
Publicado: (2022)